Symbiotec Pharmalab Limited Financial Ratios
SYMBIOTEC · Healthcare · Current price ₹1,276.4
P/E ratio
72.9x
P/B ratio
5.6x
ROE
11.7%
ROCE
13.0%
Debt / Equity
0.34
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 72.9x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 5.6x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 11.7% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 13.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.34 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Symbiotec Pharmalab Limited's latest numbers.
Symbiotec Pharmalab Limited profitability
Symbiotec Pharmalab Limited generates a return on equity of 11.7% and a return on capital employed of 13.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.34 and a P/E of 72.9x, Symbiotec Pharmalab Limited is conservatively financed. Our overall business-quality score for the company is 4.0 / 10.
Understand the ratios
More on Symbiotec Pharmalab Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.